Down 40% in 2022, this ASX 200 share is climbing amid insider buying action

Some insiders believe the current Polynovo share price has presented a buying opportunity.

| More on:
A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Polynovo shares push 2.78% higher to 92.5 cents during Monday trade 
  • A number of insiders recently purchased Polynovo shares after hitting a 52-week low of 85 cents last week 
  • The current share price weakness has created an attractive buying opportunity for investors 

The Polynovo Ltd (ASX: PNV) share price is edging higher on Monday morning, up 2.78% to 92.5 cents.

This comes as insiders have recently taken advantage of the share price weakness to purchase more shares.

Despite today's gains, the medical device company's shares have fallen 16% in a week, and 40% in 2022.

Directors top up on Polynovo shares

In its most recent statements, Polynovo revealed that a few of its directors each bought a portion of new shares.

Polynovo chair, David Williams picked up 500,000 shares through an on-market acquisition on 5 May at 86.89 cents apiece. He further added to his holding by buying another 1,000,565 shares at 89.94 cents each the following day.

In total, Mr Williams increased his portfolio by roughly 1.5 million Polynovo shares. This means that the chair now has around 20.4 million fully paid ordinary Polynovo shares across all his holdings.

In addition, non-executive director Andrew Lumsden also supplemented his portfolio with 100,000 shares on 5 May. The price paid per share was 87.31 cents.

The Polynovo shares were purchased via an on-market trade, bringing Mr Lumsden's total to 100,000 shares.

Furthermore, non-executive director Christine Emmanuel conducted a transaction of 115,000 Polynovo shares on 6 May. She ended up getting the best deal in the end, paying 85.51 cents per share.

The above transactions equate to the value of more than $1.52 million.

It appears that the directors believe that Polynovo shares may have bottomed out.

Polynovo share price snapshot

Over the past 12 months, Polynovo shares have plummeted by around 66%.

The company's share price has been moving along on a downhill trajectory since the start of July 2021.

Based on today's price, Polynovo commands a market capitalisation of roughly $595.52 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »